Physician profile
Julia E Staisch
NPI 1972868693
$21,596.94
in general payments reported to CMS, 2019-2025
20 companies · $2,116 in 2025
The $2,116 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,540 · 2020: $5,013 · 2021: $817 · 2022: $1,181 · 2023: $1,401 · 2024: $3,528 · 2025: $2,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175 · Travel and Lodging: $2,669 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,175.35 |
| Travel and Lodging | $2,669.48 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $11,030.10 | 2019-2021 | |
| Medtronic, INC. | $3,810.04 | 2021-2025 | Percept PC Brainsense, Activa PC, Bis |
| Boston Scientific Corporation | $3,581.10 | 2019-2025 | Vercise, General - Therapies, General - Dbs |
| Insightec,INC | $1,211.90 | 2024-2025 | Exablate |
| Neurocrine Biosciences, INC. | $560.60 | 2019-2023 | |
| Abbvie INC. | $438.88 | 2023-2025 | Botox, Duopa |
| Teva Pharmaceuticals USA, INC. | $248.54 | 2019-2025 | Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $139.12 | 2019-2024 | |
| Medtronic USA, INC. | $121.50 | 2019 | |
| Kyowa Kirin, INC. | $80.75 | 2021 | |
| Adamas Pharmaceuticals, INC. | $73.07 | 2019-2020 | |
| Eisai INC. | $72.38 | 2019-2025 | |
| Allergan, INC. | $59.68 | 2020-2022 | |
| Greenwich Biosciences, INC. | $43.15 | 2019 | |
| Penumbra, INC. | $31.86 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.88 | 2025 | Uplizna |
| Amneal Pharmaceuticals LLC | $19.33 | 2024 | Rytary |
| Biohaven Pharmaceutical Holding Company LTD. | $18.21 | 2022 | |
| Zyla Life Sciences, INC. | $15.74 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Staisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.